Myokardia Inc (MYOK) : Cormorant Asset Management scooped up 847,500 additional shares in Myokardia Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,605,790 shares of Myokardia Inc which is valued at $28,181,615.Myokardia Inc makes up approximately 3.17% of Cormorant Asset Management’s portfolio.
Other Hedge Funds, Including , Moore Capital Management Lp added MYOK to its portfolio by purchasing 50,000 company shares during the most recent quarter which is valued at $877,500. Myokardia Inc makes up approx 0.05% of Moore Capital Management Lp’s portfolio. Marshall Wace Llp added MYOK to its portfolio by purchasing 100,000 company shares during the most recent quarter which is valued at $1,610,000. Myokardia Inc makes up approx 0.01% of Marshall Wace Llp’s portfolio. Emerald Acquisition Ltd. added MYOK to its portfolio by purchasing 38,792 company shares during the most recent quarter which is valued at $632,310. Victory Capital Management Inc added MYOK to its portfolio by purchasing 27,180 company shares during the most recent quarter which is valued at $354,699.Strs Ohio reduced its stake in MYOK by selling 100 shares or 2.7% in the most recent quarter. The Hedge Fund company now holds 3,600 shares of MYOK which is valued at $48,240.
On the company’s financial health, Myokardia Inc reported $-0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Nov 7, 2016. Analyst had a consensus of $-0.36. The company had revenue of $3.55 million for the quarter, compared to analysts expectations of $4.84 million.
MyoKardia Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). In addition the Company is evaluating MYK-461 and initiated a Phase I clinical program for the treatment of HCM.